scholarly journals Solitary Adrenal Metastasis from Esophageal Adenocarcinoma: A Case Report and Review of the Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
D. Dellaportas ◽  
P. Lykoudis ◽  
G. Gkiokas ◽  
G. Polymeneas ◽  
A. Kondi-Pafiti ◽  
...  

Introduction. In patients with extra-adrenal malignancy, an adrenal mass necessitates investigating the possibility of metastatic tumor. Curable adrenal metastasis are considered as a rare event.Case report. A 52-year-old male suffering from lower esophageal adenocarcinoma with a solitary left adrenal metastasis is presented herein, who underwent concomitant transhiatal esophagectomy and left adrenalectomy. The patient remains disease-free 18 months later.Discussion. Adrenal metastases mostly occur in patients with lung, kidney, breast, and gastrointestinal carcinomas. Primary esophageal adenocarcinoma gives adrenal metastatic deposits according to autopsy series with an incidence of about 3%–12%. When no other evidence of metastatic disease in cancer patients exists, several authors advocate adrenalectomy with curative intent. Isolated cases of long-term survival after resection of solitary adrenal metastasis from esophageal adenocarcinoma, like in our case, have been reported only as case reports.Conclusion. This study concludes that surgical resection may result in survival benefit in selected patients with solitary adrenal metastasis from esophageal adenocarcinoma.

2021 ◽  
Vol 2021 (6) ◽  
Author(s):  
Dianne Barrett ◽  
Andrew Sumnicht ◽  
KV Chalam ◽  
Micheal Rauser

ABSTRACT Esophageal adenocarcinoma historically is an aggressive cancer with poor long-term survival. Ocular metastasis secondary to gastrointestinal malignancy is rare. In managing patients with ocular metastasis, quality of life (specifically vision preservation) is one of the most important factors patients and providers consider when deciding on a treatment regimen. Anti-programmed cell death-1 (PD-1) and PD-1 ligand (PD-L1) inhibitors such as pembrolizumab have shown promising results as second-line therapy for patient with metastatic malignancy. We describe a novel case of a functionally monocular patient with known metastatic esophageal adenocarcinoma who developed poor vision and a large choroidal lesion in his better seeing eye. The lesion regressed and vision restored to 20/20 after treatments with pembrolizumab in this case report.


2019 ◽  
Vol 80 (6) ◽  
pp. 1079-1083
Author(s):  
Kazuhisa KANESHIRO ◽  
Tadashi KAYASHIMA ◽  
Yasushi IKUTA ◽  
Yasuo MATUNARI

Cases Journal ◽  
2008 ◽  
Vol 1 (1) ◽  
Author(s):  
Christopher Kosmidis ◽  
Christopher Efthimiadis ◽  
George Anthimidis ◽  
Sofia Levva ◽  
Georgia Ioannidou ◽  
...  

2014 ◽  
Vol 63 (1) ◽  
pp. 31-35
Author(s):  
Hidefumi KUBO ◽  
Chiyo NAKASUGA ◽  
Kousuke TADA ◽  
Makoto MIYAHARA ◽  
Hiroyasu HASEGAWA ◽  
...  

2020 ◽  
Vol 53 (2) ◽  
pp. 131-138
Author(s):  
Tomoyuki Kakuta ◽  
Satoru Nakagawa ◽  
Takeo Bamba ◽  
Masaki Aizawa ◽  
Atsushi Matsuki ◽  
...  

2002 ◽  
Vol 35 (11) ◽  
pp. 1703-1707 ◽  
Author(s):  
Yasuhisa Oida ◽  
Masaya Mukai ◽  
Yuuichi Okamoto ◽  
Sayuri Mukouyama ◽  
Isao Ito ◽  
...  

2015 ◽  
Vol 100 (4) ◽  
pp. 744-747 ◽  
Author(s):  
Xiafei Hong ◽  
Wenming Wu ◽  
Mengyi Wang ◽  
Quan Liao ◽  
Yupei Zhao

We aimed to explore the optimal follow-up time for benign gastric Schwannoma. Benign gastric Schwannoma is an uncommon type of gastric neoplasias. Most of the studies are case reports and case series. Although it is generally considered to be benign, the optimal follow-up time and the chance of recurrence have not yet been investigated fully. We presented a case of benign gastric Schwannoma and systematically reviewed published case series with follow-up data. Eight studies were included, totaling 137 patients (44 male and 93 female) with the median follow-up time ranging from 22–132 months across different studies. No recurrence had been recorded during the follow-up period. Benign gastric Schwannoma rarely recurs after complete surgical resection. Long-term survival will be expected in most patients.


2017 ◽  
Vol 5 (4) ◽  
pp. 232470961774090
Author(s):  
Dat Cao Pham ◽  
Ziad Awad ◽  
Bradford S. Hoppe ◽  
Jason Hew ◽  
Ke Ning

Most extensive-stage small cell lung cancers have disseminated disease at diagnosis, and solitary adrenal metastasis from small cell lung cancer is rare. We report the case of a 51-year-old man with extensive-stage small cell lung cancer with solitary right adrenal metastasis (T2N0M1), who was cured with resection of primary tumor, chemotherapy (cisplatin, etoposide), adrenalectomy, consolidative thoracic radiotherapy, and prophylactic cranial irradiation. He remained cancer free, 7.5 years since diagnosis. For small cell lung cancer with solitary adrenal gland metastasis, metastasectomy combined with chemotherapy and radiotherapy can be curative and enable long-term survival. This treatment approach should be further studied, and similar cases should be reported.


Sign in / Sign up

Export Citation Format

Share Document